Merck’s ex-official appointed as new R&D head for Johnson & Johnson, Pharma giant opens door for further M&As
Category: #health  By Saipriya Iyer  Date: 2017-06-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck’s ex-official appointed as new R&D head for Johnson & Johnson, Pharma giant opens door for further M&As

Johnson & Johnson, Inc., one of the most reputed and popular companies operating in global pharmaceutical market, has appointed a new head - Mathai Mammen, for its research & development wing, as a part of its routine organization restructuring program. Preceding this appointment was former R&D head William Hait’s appointment as global head, J&J external innovation. Through this position, Hait aims to oversee Johnson & Johnson’s partnering portfolio, replete with numerous agreement with reputed companies all over the globe.

As per reports, Hait had already catapulted the pharma giant to a profitable position across the globe, by means of enabling lucrative partnerships and collaborations. This restructuring, say company insiders, will only serve to be highly fruitful to the organization from the business point of view. For one, Hait’s appointment as global head, J&J external innovation has entrusted him with the responsibility of the firm’s JLABS startup incubators, JJDC VC wing, and the innovation centers J&J has set up in MA, London, CA, Boston, Menlo Park, Shanghai, and United Kingdom. Hait’s decade long experience as R&D head is expected to serve him well and do justice to his new posting. The company aims to attract an extensive number of investors and strengthen their global network.

Hait’s arrival at Johnson & Johnson as the head of R&D for the hematology and oncology disciplines 10 years earlier was marred by the company’s efforts to consolidate the teams working across numerous units of aforementioned therapeutic areas. Hait however, oversaw the research with diligence and as reports have it, he successfully established J&J as a force to reckon with, by means of commercializing drugs such as Darzalex, the first monoclonal antibody that was approved by the FDA to be used in the treatment of multiple myeloma.

Mathai Mammen, one of the most prominent ex-executives of Merck, and the co-founder of Theravance Biopharma, the reputed biopharmaceutical company headquartered in San Francisco, has had an impressive record in R&D, possibly owing to which he had been lured away by J&J as the new R&D head. Mammen’s experience as a senior Vice-President in Theravance and as a senior position of R&D in Merck will help catapult Johnson & Johnson to greater heights, given that Hait has already provided Mammen with a pipeline that he reportedly mentioned was one of the most sustainable and robust ones in the industry.

This restructuring is anticipated to bring in renewed growth prospects for J&J. With Hait already having established a pipeline of lucrative mergers, Mammen’s profile has apparently turned more challenging, for which the eminent ex-Merck-executive will have to ante up his performance level and jelp Johnson & Johnson achieve its recently set targets for sales growth and new approvals.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Regeneron begins late-stage trial of its coronavirus antibody cocktail
Regeneron begins late-stage trial of its coronavirus antibody cocktail
By Saipriya Iyer

Renowned American biopharmaceutical company, Regeneron Pharmaceuticals, has reportedly announced that it has started late-stage clinical trials of its proprietary antibody cocktail to assess its effectiveness in treati...

China completes 2 launches in 3-day span with Gaofen & Shiyan-6
China completes 2 launches in 3-day span with Gaofen & Shiyan-6
By Saipriya Iyer

China has recently launched its classified Shiyan-6 (02) satellite, following the launch of Gaofen, which is a ‘multimode’ Earth observation satellite, into orbit 2 days earlier. These two launches will mar...

Tetra Pak announces target to reach net-zero GHG emissions by 2030
Tetra Pak announces target to reach net-zero GHG emissions by 2030
By Saipriya Iyer

Tetra Pak, a food processing and packaging solutions provider, has recently announced its target to reach net-zero GHG (greenhouse gas) emissions in its operations by 2030.

The targ...